Stanford



Lori Muffly

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

  875 Blake Wilbur Dr Clinic G

  MC 6555

  Stanford, CA 94305

  Tel (650) 498-6000 **Fax** (650) 498-6919

Bio

BIO

Dr. Muffly is a Professor in the Division of Blood and Marrow Transplantation-Cellular Therapies. She is an expert in cellular therapies for adults with acute leukemia. She leads several national and institutional clinical trials aimed at improving the outcomes of bone marrow transplantation and CAR T-cell therapies for adults with acute lymphoblastic leukemia and acute myeloid leukemia. She also conducts population sciences research to improve access to care and outcomes among these patient populations. She serves on the Board of Directors for NMDP, is a prior Director at Large for ASTCT, is a member of the Editorial Boards of Blood, Blood Advances, and the Hematologist, an Associate Editor for Transplantation and Cellular Therapy, and the Executive Editor of Hematology, the ASH Education Book. Her work is funded by the Leukemia and Lymphoma Society, the NIH, the California Institute of Regenerative Medicine, and various industry partners.

CLINICAL FOCUS

- blood and marrow transplant
- Hematology
- CAR T Cell Therapy
- acute lymphoblastic leukemia
- acute myeloid leukemia

ACADEMIC APPOINTMENTS

- Professor-Univ Med Line, Medicine - Blood & Marrow Transplantation
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Senior Fellow, Leukemia & Transplantation Program - University of Chicago, (2011-2013)
- Senior Fellow, Lymphoma Program, University of Chicago, (2011-2013)

- Senior Fellow, Adolescent & Young Adult Clinic, University of Chicago, (2012-2013)
- Bone Marrow Transplant Fellow, Colorado Blood Cancer Institute, Denver CO, (2013-2014)
- Clinical Assistant Professor of Medicine, Stanford University, (2014-2018)
- Assistant Fellowship Director, Stanford Blood and Marrow Transplant Division, (2016-2019)
- Faculty Director, Stanford Cancer Cell Therapy Core Database, (2018-2020)
- Assistant Professor of Medicine, Division of Blood and Marrow Transplantation Stanford University, (2018- present)
- Clinical Research Group (CRG) Leader, Stanford Blood and Marrow Transplant, (2019- present)
- Clinical Research Operations Leader, Stanford BMT-CT Division, (2019- present)

HONORS AND AWARDS

- Herbert Armory Hare Honor Medical Society, Jefferson Medical College (2007)
- Excellence in Teaching Award, Dartmouth Hitchcock Medical Center (2010)
- Illinois Medical Oncology Society Fellow Research Award Recipient, . (2012)
- NIH T32CA9566 Training Grant Recipient, . (2012)
- Richard and Debra Gonzalez Fellowship Grant Recipient, University of Chicago (2012)
- American Society of Blood & Marrow Transplantation Travel Grant Recipient, . (2013)
- Conquer Cancer Foundation of ASCO Jane C Wright, MD Young Investigator Award, . (2013)
- Palliative Care Research Cooperative Group Investigator Development Award, . (2016)
- Clinical Innovation Award, Stanford Cancer Institute (2017)
- Access to Care Award, Leukemia and Lymphoma Society (2020)
- Innovation Award, Stanford Cancer Institute (2020)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Clinical Oncology (2013 - present)
- Member, American Society of Hematology (2013 - present)
- Member, American Society for Transplantation and Cellular Therapy (2014 - present)
- Member, Stanford Cancer Institute (2014 - present)
- Member, Scientific Review Committee Panel Member, Stanford Cancer Institute (2016 - 2020)
- Member, Center for Cancer Cell Therapies (2016 - present)
- Member, Society of Hematologic Oncology (SOHO) Educational Planning Committee (2017 - present)
- Member, Center for International Blood and Marrow Transplant Late Effects Task Force (2018 - 2019)
- Member, Transplantation and Cellular Therapy Meetings (TCT) Scientific Organizing Committee (2019 - 2020)
- Member, American Society of Hematology Government Affairs Committee (2019 - present)
- Member, Bone Marrow Transplant Clinical Trials Network Publications Committee (2019 - present)
- Member, BMT Clinical Trials Network Myeloid Malignancies State of the Science Committee (2020 - present)
- Member, Center for Int'l Blood and Marrow Transplant Research Nominating Committee (2020 - present)
- Member, American Board of Internal Medicine Hematology Item Writing Task Force Committee (2020 - present)
- Co-Chair, Bone Marrow Transplant Clinical Trials Network Publications Committee (2021 - present)
- Member, Stanford Cancer Institute Data and Safety Monitoring Committee (2021 - present)

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2013)
- Medical Education: Sidney Kimmel Medical College Thomas Jefferson University (2007) PA
- Fellowship: University of Chicago Hospitals (2013) IL
- Residency: Dartmouth Hitchcock Medical Center (2010) NH
- Internship: Dartmouth Hitchock Medical Center (2008) NH

LINKS

- Get a Second Opinion: https://stanfordhealthcare.org/second-opinion/overview.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Muffly is the Principal Investigator on numerous clinical trials in the Division of BMT-CT. Her trials have included novel CAR T-cell constructs for adults with ALL and AML, including CAR T-cell therapies that have been developed and manufactured at Stanford. She has studied methods to improve CAR T-cells in adults with ALL in vivo through the use of cytokine and tyrosine kinase inhibitors. She is also interested in novel trials and approaches to transplantation, and is the Principal Investigator of an investigator initiated trial that combines a donor grant engineered transplant with allogeneic CAR T-cells for adults with high-risk ALL. She has several industry partnerships to advance science and new therapeutics in these patient populations. Aside from clinical trials, she leads a health outcomes research program that has received successive funding to study equity in access to care for young adults with acute leukemia. She has published several papers on this topic and works with researchers around the country examining large datasets to determine patterns of care and barriers to specialized cancer care. She has mentored dozens of students and trainees and serves as faculty for mentorship programs (ASH CRTI). She is also a current or past member of the Editorial Boards of Blood, Blood Advances, the Hematologist, and serves as the Executive Editor of Hematology, the ASH Annual Meeting Book.

CLINICAL TRIALS

- Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events, Recruiting
- Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT, Recruiting
- A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Not Recruiting
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants, Not Recruiting
- A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1), Not Recruiting
- A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT), Not Recruiting
- A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML), Not Recruiting
- Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies, Not Recruiting
- Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301), Not Recruiting
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies, Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant, Not Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Not Recruiting
- Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies, Not Recruiting

- Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD), Not Recruiting
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant, Not Recruiting
- JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation, Not Recruiting
- MAGE A10^{c}###T for Advanced NSCLC, Not Recruiting
- Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL, Not Recruiting
- Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Social Adaptation in Long Term Survivors of Blood and Marrow Transplantation, Not Recruiting
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors, Not Recruiting
- Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant, Not Recruiting
- Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia, Not Recruiting
- Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies, Not Recruiting
- Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
- Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia, Not Recruiting
- Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes, Not Recruiting
- Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- The clonoSEQ® Watch Registry, Not Recruiting
- Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation, Not Recruiting
- Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD), Not Specified
- Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML, Not Specified

Publications

PUBLICATIONS

- **Adoption of Pediatric-Inspired Acute Lymphoblastic Leukemia Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study** *CANCER*
  Muffly, L., Lichtensztajn, D., Shiraz, P., Abrahao, R., McNeer, J., Stock, W., Keegan, T., Gomez, S. L.
  2017; 123 (1): 122-130
- **Clonal hematopoiesis and cytopenias following CAR19 therapy.** *Nature genetics*
  Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., Alig, S. K., Good, Z., Schroers-Martin, J. G., Tamaresis, J., Esfahani, M. S., Lu, Y., Olsen, et al
  2026
- **Travel time, insurance, and specialized cancer care for adolescents and young adults with acute lymphoblastic leukemia.** *Blood neoplasia*
  Muffly, L., Miller, K., Zhang, A., Luo, J., Van Riper, D., Parsons, H. M., Keegan, T.
  2026; 3 (4): 100314
- **Philadelphia chromosome-like acute lymphoblastic leukemia: treat intensively, transplant selectively.** *Haematologica*
  Luskin, M. R., Muffly, L.
  2026
- **Trends and Predictors of Hematopoietic Cell Transplant Utilization for HIV-lymphoma in California, 1991-2016.** *Transplantation and cellular therapy*

David, K. A., Brunson, A., Fauer, A. J., Schonfeld, S. J., Chen, S., Zepf, R., Fejerman, L., Meyer, C., Auletta, J. J., Muffly, L., Morton, L. M., Catz, S. L., Keegan, et al
2026

- **Differences in Hematopoietic Cell Transplantation Outcomes by HIV status, California, 1991-2016.** *Transplantation and cellular therapy*
  David, K. A., Brunson, A., Schonfeld, S. J., Fauer, A. J., Chen, S., Zepf, R., Fejerman, L., Meyer, C., Auletta, J. J., Muffly, L., Morton, L. M., Catz, S. L., Keegan, et al
  2026
- **A Secret-Shopper Study Evaluating Logistic Barriers to Care Among Young Adults with Acute Lymphoblastic Leukemia.** *The oncologist*
  Greenwald, S., Hassan, M., Muffly, L., Miller, K., Luo, J., Zhang, A., Keegan, T. H., Parsons, H. M.
  2026
- **CAR T before the storm: early consolidation in B-ALL.** *Blood advances*
  Shouval, R., Muffly, L.
  2026; 10 (17): 6007-6008
- **Long-term lessons from CALGB 10403.** *Blood advances*
  Luo, J. W., Muffly, L. S.
  2026; 10 (16): 5592-5593
- **Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients.** *Transplantation and cellular therapy*
  Oliai, C. H., Gandhi, A., Hoeg, R. T., Muffly, L., Srour, S. A., Mehta, R. S., Waller, E. K., Lowsky, R., Patel, S. S., Dholaria, B., Pantin, J., Salhotra, A., McGuirk, et al
  2026
- **Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.** *Blood advances*
  Levis, M. J., Hamadani, M., Logan, B. R., Jones, R. J., Singh, A. K., Litzow, M. R., Wingard, J. R., Papadopoulos, E. B., Perl, A. E., Soiffer, R. J., Ustun, C., Ueda Oshima, M., Uy, et al
  2026
- **A QUEST to improve outcomes for adults with high-risk B-ALL.** *Blood*
  Srinagesh, H. K., Muffly, L. S.
  2026; 148 (3): 265-266
- **Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA).** *Transplantation and cellular therapy*
  Faramand, R. G., Zhang, A., Roloff, G. W., Aldoss, I., Advani, A. S., Battiwalla, M., Boccucci, J., Byrd, K., Cassaday, R. D., Connor, M., Dykes, K. C., Hilal, T., Kopmar, et al
  2026
- **Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.** *Blood advances*
  Othman, T., Roloff, G. W., Miller, K., Zhang, A., Sutherland, K. C., Faramand, R. G., Hill, L. C., Muhsen, I. N., Jeyakumar, N., Ladha, A., Sasine, J. P., Lin, C., Kopmar, et al
  2026
- **Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.** *Blood advances*
  Le, C. T., Zhang, A., Vyas, R. D., Otani, J., Russell, K., Cassaday, R. D., Muffly, L. S., Liang, E. C.
  2026
- **Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.** *Blood*
  Muffly, L., Frey, N. V., Roloff, G. W., Park, J. H., Dholaria, B., Advani, A. S., Bachanova, V., Cassaday, R. D., Daunov, M., Dykes, K. C., Irizarry Gatell, V., Grunwald, M. R., Hilal, et al
  2026
- **Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).** *Blood advances*
  Silva, W. F., Yin, J., Liedtke, M., Claxton, D., Fulton, N., Giri, S., Malnassy, G., Mrózek, K., Paietta, E., Mullighan, C. G., Galinsky, I. A., Bogart, J., Grecula, et al
  2026

- **A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT** *BLOOD*
  Mushtaq, M., DiPersio, J. F., Azzi, J., Cooper, B. W., Koehne, G., Koura, D., Maakaron, J., Magenau, J., McClune, B., Rimando, J. C., Shah, N. N., Suh, H. C., Beuka, et al
  2026; 147 (17): 1914-1927

- **Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia**
  Jeyakumar, N., Shiraz, P., Weber, E., Kanegai, A., Wagner, C., Ramakrishnan, A., Sahaf, B., Frank, M., Dahiya, S., Smith, M., Sidana, S., Mackall, C., Miklos, et al
  AMER ASSOC CANCER RESEARCH.2026

- **Zamtocabtagene autoleucel: dual CD20-CD19 targeting for NHL.** *Blood advances*
  Srinagesh, H. K., Muffly, L. S.
  2026; 10 (7): 2429-2430

- **Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Daver, N., Blachly, J. S., Ghobadi, A., Advani, A., Muffly, L., Garciaz, S., Recher, C., Kahali, B., Sun, J., Jung, A. S., Filosto, S., Mao, D., Granados, et al
  2026

- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*
  Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al
  2026

- **Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and cellular therapy*
  Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, et al
  2026

- **Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.** *Blood*
  Muffly, L. S., Lee, C. J., Gandhi, A., Varma, A., Scott, B. L., Patel, S. S., Shiraz, P., Youn, M., Yanagiba, C., Arulprakasam, J., Le, A., Kwon, H. S., Long-Boyle, et al
  2026

- **Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.** *Blood*
  Srinagesh, H. K., Gupta, V. K., Zhang, A., Grunwald, M. R., Connor, M. P., Kota, V. K., Boccucci, J., Ulrickson, M. L., Pradeep, R., Hill, L. C., Tsai, S. B., O'Connor, T. E., Sandhu, et al
  2026

- **Inclusion as innovation: broadening trial criteria in AML** *BLOOD*
  Kennedy, V. E., Muffly, L.
  2026; 147 (6): 604-605

- **Inclusion as innovation: broadening trial criteria in AML.** *Blood*
  Kennedy, V. E., Muffly, L.
  2026; 147 (6): 604-605

- **A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.** *Blood*
  Mushtaq, M. U., DiPersio, J. F., Azzi, J., Cooper, B. W., Koehne, G., Koura, D., Maakaron, J. E., Magenau, J. M., McClune, B., Rimando, J. C., Shah, N. N., Suh, H. C., Beuka, et al
  2026

- **Superior Long-Term Survival with Fludarabine-Melphalan RIC Regimen in Older AML/MDS Patients: A Propensity Score Analysis of CIBMTR Data**
  Kongtim, P., Portuguese, A. J., Soyoung, K., Peterson, A., Elmariah, H., Muffly, L. S., Juckett, M. B., Grunwald, M., Nawas, M., Bejanyan, N., Jain, T., Bachanova, V., Bi, et al
  ELSEVIER SCIENCE INC.2026: S53-S54

- **Centering Patient Voices to Validate a Health-Related Social Needs Data Collection Tool for BMT and Cellular Therapy**
  Maeyama, J., Kalapurakkel, S., Johnson, C., Muffly, L. S.
  ELSEVIER SCIENCE INC.2026

- **Outcomes of Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Recipients or Donors with Deleterious Likely Germline Variants**
  Stubbins, R. J., Trottier, A. M., Hattig, Z. S., V. Rodgers, C., Haribabu, Y., Crone, L., Govaerts, I., Smith, W., Zhang, T., Bolon, Y., Grunwald, M. R., Jain, T., Juckett, et al
  ELSEVIER SCIENCE INC.2026

- **Impact of IMWG Frailty and Nutritional Biomarkers on Outcomes in MM Pts Undergoing ASCT**
  Uzun, D., Zhang, A., Austin, R., Yeung, S. B., Kondapally, Y. R., Jensen, A., Hovanky, V., Rana, M., Shizuru, J. A., Arai, S., Rezvani, A. R., Bharadwaj, S., Lowsky, et al
  ELSEVIER SCIENCE INC.2026

- **The Relationship of Baseline and Longitudinal Frailty and Inflammatory Biomarkers with CAR-T Treatment Outcomes in Relapsed Refractory Myeloma**
  Yeung, S. B., Kondapally, Y. R., Uzun, D., Zhang, A., Austin, R., Jensen, A., Hovanky, V., Rana, M., Shizuru, J. A., Arai, S., Rezvani, A. R., Bharadwaj, S., Lowsky, et al
  ELSEVIER SCIENCE INC.2026

- **Impact of Baseline and Dynamic IMWG Simplified Frailty Scores on Outcomes after CAR T-cell and Bispecific Antibody Therapy in Multiple Myeloma**
  Zhang, A., Uzun, D., Yeung, S. B., Kondapally, Y. R., Austin, R., Jensen, A., Hovanky, V., Rana, M., Shizuru, J. A., Arai, S., Rezvani, A. R., Bharadwaj, S., Lowsky, et al
  ELSEVIER SCIENCE INC.2026

- **Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients**
  Rana, M., Kaveh, N., Jensen, A., Kennedy, V. E., Weng, W., Smith, M., Shiraz, P., Jandir, N., Latchford, T. M., Frank, M., Bharadwaj, S., Dahiya, S., Miklos, et al
  ELSEVIER SCIENCE INC.2026

- **Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy**
  Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Lowsky, R., Meyer, E. H., Mikkilineni, L., Muffly, et al
  ELSEVIER SCIENCE INC.2026

- **Patterns of Solid Tumor Risk after HCT Based on a Population-Based CIBMTR and California Cancer Registry Linked Dataset**
  Schonfeld, S. J., Meyer, C. L., Shaw, B. E., Phelan, R., Rizzo, J., Brunson, A., Curtis, R., Wun, T., Auletta, J. J., Muffly, L. S., Keegan, T. H. M., Morton, L. M.
  ELSEVIER SCIENCE INC.2026

- **High Molecular Weight Isoforms of Thymic Stromal Lymphopoietin Correlate with Presence and Severity of Acute Graft Versus Host Disease**
  Shiraz, P., Louloudis, I., Liliental, J. A., Muffly, L. S., Kennedy, V. E., Patel, S., Negrin, R. S., Lowsky, R., Arai, S., Johnston, L., Rezvani, A. R., Weng, W., Bharadwaj, et al
  ELSEVIER SCIENCE INC.2026: S46-S47

- **Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucel and Brexucabtagene Autoleucel for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis**
  Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Danley, L., Ramakrishnan, A., Daghagh, H., Huang, Y., Dhapola, G., Siddiqui, A., Arai, et al
  ELSEVIER SCIENCE INC.2026: S27

- **Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.** *Blood cancer discovery*
  Srinagesh, H. K., Kramer, A. M., Baird, J. H., Reschke, A., Sahaf, B., Cancilla, J., Syal, S., Su, Y. J., Agarwal, N., Jensen, A. M., Schultz, L. M., Jeyakumar, N., Ramakrishna, et al
  2025

- **Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation**

Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, L., Lowsky, et al

ELSEVIER.2025: 2494-2495

- **CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma**

  Kramer, A., Murty, T., Chen, Y., Rodrigues, K., Hamilton, M., Desai, M., Kuo, A., Ehlinger, Z., Reynolds, W., Srinagesh, H., Tsui, K., Rietberg, S., Mo, et al

  ELSEVIER.2025: 566-567

- **Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study**

  Lee, D., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., Desai, M., Mallampet, J., Lohman, C., Huang, Y., Kang, X., Tian, F., Mutter, et al

  ELSEVIER.2025: 671-672

- **Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world**

  Logan, A., Yalniz, F., Zhang, A., Miller, K., Sutherland, K., Jeyakumar, N., Srinagesh, H., Grunwald, M., Kota, V., Boccucci, J., Ulrickson, M., Al-Darobi, A., Sasine, et al

  ELSEVIER.2025: 516-517

- **Pre-treatment CDI9 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL**

  Spiegel, J., Oak, J., Rana, M., Jensen, A., Lee, D., Nguyen-Mau, S., Kong, K., Bornheimer, S., Mikkilineni, L., Muffly, L., Sidana, S., Weng, W., Bharadwaj, et al

  ELSEVIER.2025: 5882-5883

- **CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel**

  Mccauley, R., Zhang, A., Kota, V., Boccucci, J., Grunwald, M., Ulrickson, M., Hill, L., Muhsen, I., Sasine, J., Advani, A., Aldoss, I., Sandhu, K., Reshef, et al

  ELSEVIER.2025: 2396-2397

- **Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)**

  Hussain, R., Farag, Y., Patel, A., Srinagesh, H., Muffly, L., Sahaf, B., Miklos, D., Ferrari, M., Day, W., Lao-Sirieix, P.

  ELSEVIER.2025: 2367-2368

- **Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results**

  Schultz, L., Aftandilian, C., Baggott, C., Corwin, N., Fujimoto, M., Li, A., Mavroukakis, S., Moon, J., Sahaf, B., Jacobs, A., Mendoza, C., Levenson, A., Frank, et al

  ELSEVIER.2025: 2374

- **Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study**

  Villar-Prados, A., Kim, P., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, et al

  ELSEVIER.2025: 111-112

- **Donor-derived CD7 CAR-T in T-ALL/LBL: promise and pitfalls.** *Blood*

  Aldoss, I., Muffly, L.

  2025; 146 (23): 2731-2732

- **Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort.** *Blood cancer journal*

  Elias, S., Brown, S., Egini, O., Walji, M., Homsy, S., Velayati, A., Devlin, S., Ponce, D. M., Kennedy, V., Bharadwaj, S., Shiraz, P., Jakubowski, A. A., Papadopoulos, et al

  2025; 15 (1): 208

- **KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel(Brexu-cel)**

  Leonard, J., Ladha, A., Faramand, R., Roloff, G., Valtis, Y., Tan, V., Miller, K., Zhang, A., Grunwald, M., Kota, V., Boccucci, J., Ulrickson, M., Al-Darobi, et al

ELSEVIER.2025: 3365-3367

- **The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission**
  Yu, K., Dillon, L., Tettero, J., Gui, G., Al-Ali, R., Grunwald, M., Krakow, E., Griffiths, E., Gomez-Arteaga, A., Vedula, R., Solh, M., Salhotra, A., Bejanyan, et al
  ELSEVIER.2025: 455-456

- **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**
  Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al
  ELSEVIER.2025: 2525-2526

- **A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)**
  Muffly, L., Abadir, E., Geyer, M., Cassaday, R., Roloff, G., Sica, R., Stock, W., Mcnulty, E., Del Rosario, M., Shi, X., Liu, Y., Yu, Y., Zhou, et al
  ELSEVIER.2025: 5954-5955

- **Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease**
  Shiraz, P., Louloudis, L., Liliental, J., Patel, S., Jensen, A., Fonseca, S., Le, K., Diallo, B., Pavlova, A., Arai, S., Negrin, R., Rezvani, A., Johnston, et al
  ELSEVIER.2025: 586-587

- **Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL**
  Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Srinagesh, H., Danley, L., Ramakrishnan, A., Daghagh, H., Huang, Y., Dhapola, G., Siddiqui, et al
  ELSEVIER.2025: 514-515

- **Incidence and risk factors for CNS relapse in adult ALL after allogeneic hematopoietic cell transplant**
  Le, C., Zhang, A., Vyas, R., Otani, J., Russell, K., Cassaday, R. D., Muffly, L., Liang, E.
  ELSEVIER.2025: 6038-6039

- **Real-world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/ refractory or measurable residual disease-positive B-cell acute lymphoblastic leukemia: A CIBMTR database analysis**
  Saber, W., Brazauskas, R., Patel, J., Patel, M., Muffly, L., Juckett, M., Grunwald, M., Bejanyan, N., Jain, T., Bachanova, V., Jo, H., Zou, B., Choudhry, et al
  ELSEVIER.2025: 6044-6045

- **Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis**
  Valtis, Y., Sandhu, K., Faramand, R., Zhang, A., Miller, K., Hill, L., Muhsen, I., Othman, T., Luskin, M., Chen, E., Oliai, C., Lill, G., Cassaday, et al
  ELSEVIER.2025: 2715-2716

- **Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data**
  Kongtim, P., Portuguese, A., Kim, S., Peterson, A., Elmariah, H., Muffly, L., Juckett, M., Grunwald, M., Nawas, M., Bejanyan, N., Jain, T., Bachanova, V., Bi, et al
  ELSEVIER.2025: 109-110

- **Travel time and insurance status as determinants of specialized leukemia care access in adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)**
  Muffly, L., Parsons, H., Miller, K., Luo, J., Zhang, A., Keegan, T.
  ELSEVIER.2025: 283-284

- **Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib**
  Levis, M., Hamadani, M., Logan, B., Jones, R., Singh, A., Litzow, M., Wingard, J., Papadopoulos, E., Perl, A., Soiffer, R., Ustun, C., Oshima, M., Uy, et al
  ELSEVIER.2025: 1058-1059

- **Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506**
  Abedin, S., Baidoo, V., Szabo, A., Jones, R., Singh, A., Litzow, M., Wingard, J., Papadopoulos, E., Perl, A., Soiffer, R., Ustun, C., Oshima, M., Uy, et al

ELSEVIER.2025: 170-171

- **Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)**
  Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., Iberri, D., Liedtke, M., Bharadwaj, S., Kennedy, V., Arai, S., Shiraz, P., Weng, et al
  ELSEVIER.2025: 4586-4587

- **CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity**
  Srinagesh, H., Kramer, A., Hamilton, M., Su, Y., Kozy, K., Jackson, L., Brown, A., Denoble, K., Mavroukakis, S., Lohman, C., Cunanan, K., Agarwal, N., Bharadwaj, et al
  ELSEVIER.2025: 4159-4160

- **Cytokine-engineered CART-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia** *LANCET HAEMATOLOGY*
  Faramand, R. G., Muffly, L.
  2025; 12 (11): e853-e855

- **CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.** *Research square*
  Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., Alig, S. K., Good, Z., Schroers-Martin, J. G., Tamaresis, J., Esfahani, M. S., Lu, Y., Olsen, et al
  2025

- **Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia.** *The Lancet. Haematology*
  Faramand, R. G., Muffly, L.
  2025

- **CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.** *Blood advances*
  Valtis, Y. K., Lin, C., Nemirovsky, D., Devlin, S. M., Rejeski, K., Curran, K. J., Wang, X., Shah, N. N., Jeyakumar, N., Miller, K., Zhang, A., Kota, V. K., Al Darobi, et al
  2025

- **Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies.** *Cytotherapy*
  Dreyzin, A., Kramer, A. M., Yates, B., Wang, H. W., Sahaf, B., Yuan, C., Klysz, D., Tunuguntla, R., Ehlinger, Z., Reitberg, S., Adebola, S., Su, A., Ebina-Shibuya, et al
  2025: 101990

- **Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).** *JCO precision oncology*
  Koehne, G., Mushtaq, M. U., Muffly, L. S., Menes, M., Azzi, J., Bernard, L., Cooper, B., Kennedy, V., Koura, D., Maakaron, J., Magenau, J., McClune, B., Patel, et al
  2025; 9: e2500556

- **Hematopoietic Cell Transplantation, Version 3.2025** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Loren, A. W., Mielcarek, M., Bolanos-Meade, J., Brammer, J., Cowden, M., Di Stasi, A., El-Jawahri, A., Elmariah, H., Gundabolu, K., Gutman, J., Ho, V., Hoeg, R. T., Horwitz, et al
  2025; 23 (10)

- **Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma**
  Moscvin, M., Goyal, A., Jensen, A., Epstein, D., Hovanky, V., Mikkilineni, L., Bennett, L., Latchford, T., Arai, S., Bharadwaj, S., Frank, M., Dahiya, S., Muffly, et al
  CIG MEDIA GROUP, LP.2025

- **The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024.** *Transplantation and cellular therapy*
  Uzun, D., Paul, J. M., Jensen, A., Tamaresis, J., Domingo, W., Arai, S., Ventura, F. A., Rocha, J., Bennett, L., Jones, A., Bharadwaj, S., Johnston, L., Lowsky, et al
  2025

- **The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.** *Bone marrow transplantation*

O'Connor, T. E., Lin, C., Roloff, G. W., Zhang, A., Miller, K., Aldoss, I., Kopmar, N. E., Dekker, S. E., Gupta, V. K., Jeyakumar, N., Muhsen, I. N., Valtis, Y., Ahmed, et al

2025

- **Real-world performance of the CALGB 10403 regimen in young adults in the United States.** *Blood neoplasia*

  DaSilva, B., Darwin, A., Zhang, A., Vyas, R. D., Russell, K., Gilbert, J. S., Tan, V., Feldt, S., Johnston, H., Liang, E. C., DuVall, A. S., Liedtke, M., Stock, et al

  2025; 2 (3): 100111

- **Complexities of Measurable Residual Disease Assays in Acute Lymphoblastic Leukemia: A Guide for the Practicing Clinician.** *Acta haematologica*

  Luo, J., Muffly, L.

  2025: 1-8

- **Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.** *Blood advances*

  Levis, M. J., Hamadani, M., Logan, B. R., Jones, R. J., Singh, A. K., Litzow, M. R., Wingard, J. R., Papadopoulos, E. B., Perl, A. E., Soiffer, R. J., Ustun, C., Ueda Oshima, M., Uy, et al

  2025

- **Intraday extreme risk spillovers and portfolio in energy sector** *APPLIED ECONOMICS*

  Luo, J., Zhou, Q., He, Z.

  2025: 1-8

- **Allogeneic hematopoietic cell transplantation for acute leukemia patients not in complete remission**

  Elias, S., Brown, S., Egini, O., Walji, M., Homsy, S., Velayati, A., Devlin, S., Ponce, D., Kennedy, V., Bharadwaj, S., Shiraz, P., Jakubowski, A. A., Papadopoulos, et al

  LIPPINCOTT WILLIAMS & WILKINS.2025

- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.** *Blood advances*

  Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al

  2025

- **Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement.** *Blood advances*

  Muhsen, I. N., Roloff, G. W., Faramand, R. G., Othman, T., Valtis, Y. K., Kopmar, N. E., Dekker, S. E., Connor, M., Mercadal, S., O'Connor, T. E., Dykes, K. C., Ahmed, M., Jeyakumar, et al

  2025

- **Humanizing CAR T-cell therapy in B-ALL.** *Blood advances*

  Faramand, R., Muffly, L.

  2025; 9 (8): 1916-1917

- **Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy.** *Blood advances*

  Lust, H., Schultz, L. M., Kwon, S., Roloff, G. W., Aldoss, I., Baggott, C., John, S., Rossoff, J., McNerney, K. O., Fabrizio, V. A., Talano, J. A., Moskop, A., Curran, et al

  2025

- **Specialized Cancer Care for Adolescent and Young Adult Acute Lymphoblastic Leukemia: Barriers and Opportunities.** *Journal of the National Comprehensive Cancer Network : JNCCN*

  Muffly, L., Keegan, T. H., Mui, H. Z., Alvarez, E. M., Siden, R., Holdsworth, L. M., Parsons, H. M.

  2025: 1-7

- **CAR and ALL Hematotox Scores Predict Toxicity and Outcomes Among Recipients of Brexucabtagene Autoleucel for R/R ALL in the Real World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) Consortium**

  Valtis, Y., Lin, C., Nemirovsky, D., Devlin, S., Rejeski, K., Shah, N. N., Nair, M. S., Jeyakumar, N., Miller, K., Zhang, A., Grunwald, M. R., Kota, V., Boccucci, et al

  ELSEVIER SCIENCE INC.2025: S8-S10

- **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.** *Blood*

  Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al

2025

- **Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.** *Cancer discovery*

  Su, Y. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., Sahaf, B., Kuo, A., Ehlinger, Z. J., Desai, M. H., Rietberg, S. P., Tunuguntla, R., Patel, et al

  2025

- **Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.** *Blood*

  Levis, M. J., Hamadani, M., Logan, B. R., Jones, R. J., Singh, A. K., Litzow, M. R., Wingard, J. R., Papadopoulos, E. B., Perl, A. E., Soiffer, R. J., Ustun, C., Ueda Oshima, M., Uy, et al

  2025

- **Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.** *Bone marrow transplantation*

  Chin, M. M., Tamaresis, J. S., Johnston, L. J., Lowsky, R., Meyer, E., Muffly, L., Shiraz, P., Frank, M. J., Rezvani, A. R., Bharadwaj, S., Weng, W. K., Shizuru, J. A., Arai, et al

  2024

- **Prognostic Significance of Low Copy Number FLT3 and NPM1 mrd As Detected By Ultra-Sensitive Next Generation Sequencing**

  Shannon, M. L., Zhang, T. Y., Muffly, L., Mannis, G. N.

  ELSEVIER.2024: 4330-4331

- **CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)**

  Kramer, A., Murty, T., Chen, Y., Srinagesh, H., Hamilton, M. P., Mo, K. C., Prabhu, S., Desai, M., Kuo, A., Ehlinger, Z., Reynolds, W. D., Baird, J. H., Su, et al

  ELSEVIER.2024: 911-912

- **Identifying Disparities in Autologous Hematopoietic Cell Transplantation (autoHCT) Utilization for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in California**

  Esteghamat, N. S., Brunson, A., Abrahao, R., Rosenberg, A. S., Schonfeld, S. J., Meyer, C. L., Auletta, J. J., Cooley, J. J. P., Muffly, L., Morton, L. M., Wun, T., Keegan, T. H. M.

  ELSEVIER.2024: 2360-2361

- **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**

  Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al

  ELSEVIER.2024: 2006-2007

- **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**

  Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al

  ELSEVIER.2024: 70-71

- **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**

  Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al

  ELSEVIER.2024: 96-97

- **Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry**

  Wudhikarn, K., Bezerra, E., Yang, Y., Perales, M., Jain, N., Gergis, U., Aribi, A., Hill, L., Leonard, J. T., Lutfi, F., Kim, S., Bye, M., Hu, et al

  ELSEVIER.2024: 5092-5093

- **Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above**

  Muhsen, I., Advani, A. S., Roloff, G. W., Jeyakumar, N., Miller, K., Zhang, A., Sutherland, K. C., Grunwald, M. R., Kota, V. K., Boccucci, J., Ulrickson, M., Sasine, J., Aldoss, et al

  ELSEVIER.2024: 523-526

- **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma**
  Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
  ELSEVIER.2024: 4846-4847

- **Identifying Disparities in Autologous Hematopoietic Cell Transplantation (autoHCT) Utilization for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in California**
  Esteghamat, N. S., Brunson, A., Abrahao, R., Rosenberg, A. S., Schonfeld, S. J., Meyer, C. L., Auletta, J. J., Cooley, J. J. P., Muffly, L., Morton, L. M., Wun, T., Keegan, T. H. M.
  ELSEVIER.2024: 2360-2361

- **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**
  Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
  ELSEVIER.2024: 2006-2007

- **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
  Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
  ELSEVIER.2024: 70-71

- **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
  Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
  ELSEVIER.2024: 96-97

- **Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry**
  Wudhikarn, K., Bezerra, E., Yang, Y., Perales, M., Jain, N., Gergis, U., Aribi, A., Hill, L., Leonard, J. T., Lutfi, F., Kim, S., Bye, M., Hu, et al
  ELSEVIER.2024: 5092-5093

- **Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above**
  Muhsen, I., Advani, A. S., Roloff, G. W., Jeyakumar, N., Miller, K., Zhang, A., Sutherland, K. C., Grunwald, M. R., Kota, V. K., Boccucci, J., Ulrickson, M., Sasine, J., Aldoss, et al
  ELSEVIER.2024: 523-526

- **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma**
  Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
  ELSEVIER.2024: 4846-4847

- **Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Roloff, G. W., Aldoss, I., Kopmar, N. E., Lin, C., Dekker, S. E., Gupta, V. K., O'Connor, T. E., Jeyakumar, N., Muhsen, I. N., Valtis, Y., Ahmed, N., Zhang, A., Miller, et al
  2024: JCO2400321

- **Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.** *Blood cancer journal*
  Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J., Le, A., Muffly, L. S., Maysel-Auslender, S., Johnston, L., Arai, S., Lowsky, R., Meyer, et al
  2024; 14 (1): 173

- **PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS**
  Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, S., Shiraz, et al
  SPRINGERNATURE.2024: 287-288

- **The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Othman, T., Logan, A. C., Muffly, L., Leonard, J., Park, J., Shah, B., Aldoss, I.
  2024; 22 (8)
- **Predicting relapse in acute lymphoblastic leukemia.** *Leukemia & lymphoma*
  Schwartz, M. S., Muffly, L. S.
  2024: 1-7
- **Utilization of allogeneic hematopoietic stem cell transplantation among patients with newly diagnosed acute myeloid leukemia in California: a population-based linked dataset study.** *Haematologica*
  Meyer, C. L., Keegan, T. H., Brunson, A., Auletta, J. J., Morton, L. M., Wun, T., Schonfeld, S. J., Valcarcel, B., Abrahão, R., Yusuf, R. A., Muffly, L.
  2024
- **Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL.** *Blood advances*
  Aldoss, I., Roloff, G. W., Faramand, R. G., Kopmar, N. E., Lin, C., Advani, A. S., Dekker, S. E., Gupta, V. K., O'Connor, T. E., Jeyakumar, N., Muhsen, I. N., Valtis, Y. K., Zhang, et al
  2024
- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
  Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
  2024
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
  Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
  2024
- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
  Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
  2024; 12 (7)
- **Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry.** *Blood advances*
  Schonfeld, S. J., Valcarcel, B., Meyer, C. L., Shaw, B. E., Phelan, R., Rizzo, D., Brunson, A., Cooley, J. J., Abrahao, R., Wun, T., Gadalla, S. M., Engels, E. A., Albert, et al
  2024
- **Travel-Time barriers to specialized cancer care for adolescents and young adults with acute leukemia.** *JNCI cancer spectrum*
  Parsons, H. M., Muffly, L. S., Garcia, A., Zhang, A., Miller, K., Van Riper, D., Knowles, K., Keegan, T. H.
  2024
- **How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL.** *Blood*
  Muffly, L., Liang, E. C., Dolan, J. G., Pulsipher, M. A.
  2024
- **Management of post-autologous transplant relapse in patients with T-cell lymphomas.** *American journal of hematology*
  Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Shizuru, J., Meyer, E., Muffly, L., Rezvani, A. R., Shiraz, P., Sidana, S., Dahiya, et al
  2024
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
  Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
  2024
- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*
  Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al

2024

- **Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

  Levis, M. J., Hamadani, M., Logan, B., Jones, R. J., Singh, A. K., Litzow, M., Wingard, J. R., Papadopoulos, E. B., Perl, A. E., Soiffer, R. J., Ustun, C., Ueda Oshima, M., Uy, et al

  2024: JCO2302474

- **CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL** *American Society of Hematology*

  Mo, K. C., Yeh, C. Y., Hamilton, M. P., Spiegel, J., Desai, M., Ehlinger, Z., Reynolds, W. D., Yang, E., Ozawa, M. G., Chen, Y., Prabhu, S., Frank, M. J., Muffly, et al

  2024

- **Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study.** *Clinical lymphoma, myeloma & leukemia*

  Esteghamat, N. S., Brunson, A., Rosenberg, A. S., Schonfeld, S. J., Valcarcel, B., Abrahao, R., Cooley, J. J., Meyer, C. L., Auletta, J. J., Morton, L. M., Muffly, L., Wun, T., Keegan, et al

  2023

- **Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.** *Blood advances*

  Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., Johnston, L. J., Rezvani, A. R., Weng, W. K., Miklos, D. B., Frank, M. J., Tamaresis, J. S., Agrawal, et al

  2023

- **Comparison of vital status, cause of death, and follow-up after HCT in linked CIBMTR and California Cancer Registry data, 1991-2018.** *Transplantation and cellular therapy*

  Valcarcel, B., Schonfeld, S. J., Meyer, C. L., Brunson, A., Cooley, J. J., Abrahão, R., Wun, T., Auletta, J. J., Gadalla, S. M., Engels, E., Albert, P. S., Spellman, S. R., Rizzo, et al

  2023

- **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**

  Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al

  AMER SOC HEMATOLOGY.2023

- **Update for the 'Watch' Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies**

  Cowan, A. J., Patel, K., Svoboda, J., Shah, B. D., Cheson, B. D., Azzi, G., Rabara, V., Muffly, L. S., Simmons, H., Thuillier, S., Leonard, J. T.

  AMER SOC HEMATOLOGY.2023

- **Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the RealWorld Outcomes Collaborative of CAR T in Adult ALL (ROCCA)**

  Lin, C., Tsai, S. B., Roloff, G. W., Zhang, A., Aldoss, I., Kopmar, N. E., Dekker, S. E., Jeyakumar, N., Gupta, V. K., O'Connor, T. E., Dykes, K. C., Ahmed, M., Dholaria, et al

  AMER SOC HEMATOLOGY.2023

- **The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)**

  Aldoss, I., Roloff, G. W., Advani, A. S., Kopmar, N. E., Lin, C., Dekker, S. E., Gupta, V. K., Jeyakumar, N., O'Connor, T. E., Zhang, A., Miller, K., Dykes, K. C., Ahmed, et al

  AMER SOC HEMATOLOGY.2023

- **Discordance between Next Generation Sequencing and BCR-ABL PCR Measurable Residual Disease in Adult Patients with Ph plus Acute Lymphoblastic Leukemia**

  Dekker, S. E., Sabile, J., Dasilva, B., Saygin, C., Schwartz, M., Raman, H. S., Kaempf, A., Luskin, M. R., Patel, A., Muffly, L. S., Leonard, J. T.

  AMER SOC HEMATOLOGY.2023

- **Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation**

  Shah, N. N., Azzi, J., Cooper, B. W., Deol, A., DiPersio, J., Koura, D., McClune, B., Muffly, L. S., Mushtaq, M., Narayan, R., Suh, H., Yanik, G., Nath, et al

  AMER SOC HEMATOLOGY.2023

- **The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia**
  O'Connor, T. E., Lin, C., Roloff, G. W., Zhang, A., Aldoss, I., Faramand, R., Kopmar, N. E., Dykes, K. C., Jeyakumar, N., Dekker, S. E., Gupta, V. K., Ahmed, M., Logan, et al
  AMER SOC HEMATOLOGY.2023

- **Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/ Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study**
  Kopmar, N. E., Gooley, T., Roloff, G. W., Aldoss, I., Lin, C., Dekker, S. E., Gupta, V. K., Jeyakumar, N., O'connor, T., Dykes, K. C., Ahmed, M., Zambrano, H., Bradshaw, et al
  AMER SOC HEMATOLOGY.2023

- **Age-Related Differences in Utilization of Allogeneic HCT for Acute Myeloid Leukemia in California: Results of a Population-Based, Novel Linked Dataset**
  Meyer, C. L., Keegan, T. H. M., Brunson, A., Auletta, J. J., Morton, L. M., Wun, T., Schonfeld, S. J., Valcarcel, B., Abrahao, R., Yusuf, R., Muffly, L. S.
  AMER SOC HEMATOLOGY.2023

- **Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)**
  Gupta, V. K., Roloff, G. W., Muffly, L. S., Aldoss, I., Kopmar, N. E., Lin, C., Dekker, S. E., Jeyakumar, N., O'Connor, T. E., Zhang, A., Miller, K., Dykes, K. C., Ahmed, et al
  AMER SOC HEMATOLOGY.2023

- **Brexucabtagene Autoleucel in Adults with Relapsed/ Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)**
  Roloff, G. W., Aldoss, I., Kopmar, N. E., Lin, C., Dekker, S. E., Gupta, V. K., Jeyakumar, N., O'Connor, T. E., Zhang, A., Miller, K., Dykes, K. C., Ahmed, M., Zambrano, et al
  AMER SOC HEMATOLOGY.2023

- **Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3ITD Variant Allele Frequency and Survival Are Highly Correlated**
  Levis, M. J., Hamadani, M., Logan, B. R., Jones, R. J., Singh, A. K., Litzow, M. R., Wingard, J. R., Papadopoulos, E. B., Perl, A., Soiffer, R. J., Ustun, C., Oshima, M., Uy, et al
  AMER SOC HEMATOLOGY.2023

- **Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment**
  DaSilva, B., Vyas, R. D., Darwin, A., Russel, K., Gilbert, J., Tan, V., Darji, H., Miller, K., Liang, E. C., Raychaudhuri, S., Duvall, A. S., Liedtke, M., Stock, et al
  AMER SOC HEMATOLOGY.2023

- **CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-. Cytokine Signature**
  Srinagesh, H., Baird, J. H., Agarwal, N., Su, Y., Kramer, A., Reschke, A., Jeyakumar, N., Bharadwaj, S., Schultz, L., Ramakrishna, S., Davis, K. L., Sahaf, B., Feldman, et al
  AMER SOC HEMATOLOGY.2023

- **Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible**
  Su, Y., Kramer, A., Hamilton, M. P., Agarwal, N., Feldman, S., Sahaf, B., Kuo, A., Mackall, C. L., Muffly, L. S., Miklos, D. B., Frank, M. J.
  AMER SOC HEMATOLOGY.2023

- **Transcriptional Profiling Associated with CD22 CAR T Cell Clinical Response in LBCL**
  Kramer, A., Hamilton, M. P., Prabhu, S., Desai, M., Kuo, A., Ehlinger, Z., Agarwal, N., Su, Y., Gkitsas, N., Fowler, C., Keerthi, V., Retherford, A., Klysz, et al
  AMER SOC HEMATOLOGY.2023

- **Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation**
  Gandhi, A., Artz, A., Lee, C. J., Varma, A., Scott, B. L., Kwon, H., Youn, M., Yanagiba, C., Arulprakasam, J., Le, A., Shizuru, J., Pang, W. W., Muffly, et al
  AMER SOC HEMATOLOGY.2023

- **Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus**
  Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Miklos, D. B., Muffly, L. S., Dahiya, S., Rezvani, A. R., Sidana, et al
  AMER SOC HEMATOLOGY.2023

- **Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies**
  Oliai, C. H., Pantin, J. M., Hoeg, R. T., Muffly, L. S., Patel, S. S., Gandhi, A., Lowsky, R., Salhotra, A., Dholaria, B., Waller, E. K., Srour, S. A., Pavlova, A., Fernhoff, et al
  AMER SOC HEMATOLOGY.2023

- **PRECISION-ENGINEERED CELL THERAPY ORCA-T DEMONSTRATES HIGH RELAPSE-FREE SURVIVAL AT 1 YEAR WHILE REDUCING GRAFT-VERSUS-HOST DISEASE AND TOXICITY**
  Oliai, C., Hoeg, R., Pavlova, A., Gandhi, A., Muffly, L., Mehta, R., Srour, S., Waller, E., Lowsky, R., Patel, S., Dholaria, B., Pantin, J., Salhotra, et al
  SPRINGERNATURE.2023: 230-231

- **SOCIAL FUNCTIONING AFTER TRANSPLANTATION AND CELLULAR THERAPY: INITIAL PATIENT-REPORTED OUTCOMES RESULTS FROM THE CIBMTR**
  Cusatis, R., Ndifon, E., Mattila, D., Berman, L., Akinola, I., Kapfhammer, M., Jacox, C., Luetke, C., Hamilton, B., Muffly, L., Shaughnessy, P., Shaw, B., Flynn, et al
  SPRINGERNATURE.2023: 700

- **GVHD ASSESSMENT IN PHASE 1 STUDY OF BRIQUILIMAB (JSP191), LOW DOSE IRRADIATION AND FLUDARABINE CONDITIONING IN OLDER ADULTS WITH MDS/AML UNDERGOING ALLOGENEIC HCT**
  Youn, M., Muffly, L., Artz, A., Lee, C., Gandhi, A., Varma, A., Scott, B., Yanagiba, C., Tiwari, R., Arulprakasam, J., Le, A., Shizuru, J., Kwon, et al
  SPRINGERNATURE.2023: 306-307

- **Impact of Specialized Treatment Setting on Survival in Adolescent and Young Adult ALL.** *JCO oncology practice*
  Muffly, L. S., Parsons, H. M., Miller, K., Li, Q., Brunson, A., Keegan, T. H.
  2023: OP2300373

- **Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.** *Blood cancer journal*
  Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., Sahaf, B., Bharadwaj, S., Latchford, T., Arai, S., Leahy, S., Mei, M., Budde, et al
  2023; 13 (1): 158

- **INSPIRED Symposium Part 4A: Access to CAR T cell Therapy in Unique Populations with B-cell Acute Lymphoblastic Leukemia.** *Transplantation and cellular therapy*
  Winestone, L. E., Bhojwani, D., Ghorashian, S., Muffly, L., Leahy, A. B., Chao, K., Steineck, A., Rossig, C., Lamble, A., Maude, S. L., Myers, R., Rheingold, S. R.
  2023

- **Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)**
  Burns, L. J., Pandya, B. J., Chen, K., Wang, T., Xie, B., Touya, M., Spalding, J., Block, A., Kuperman, G., Young, C., Muffly, L.
  CIG MEDIA GROUP, LP.2023: S276

- **Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease (GvHD) and Toxicity**
  Salhotra, A., Oliai, C., Hoeg, R. T., Gandhi, A., Muffly, L., Srour, S. A., Waller, E., Lowsky, R., Patel, S., Pantin, J., Dholaria, B., Pavlova, A., Fernhoff, et al
  CIG MEDIA GROUP, LP.2023: S316-S317

- **Implementation of a Pilot Clinic for Pediatric to Adult Cancer Survivorship Transitions.** *Journal of adolescent and young adult oncology*
  Jin, A. H., Simon, P. J., Clayton, A., Benedict, C., Liedtke, M., Muffly, L., Schapira, L., Smith, S. M.
  2023

- **Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.** *Leukemia & lymphoma*
  Muffly, L., Young, C., Feng, Q., Nimke, D., Pandya, B. J.

2023: 1-8

- **Specialty cancer care and survival in AYA ALL: A US multi-state analysis.**
  Muffly, L. S., Miller, K., Maguire, F., Li, Q., Parsons, H. M., Keegan, T.
  LIPPINCOTT WILLIAMS & WILKINS.2023

- **Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.**
  Roloff, G., Faramand, R., Aldoss, I., Kopmar, N., Schwartz, M., Dekker, S. E., Lin, C., Tracy, S., Vilchez, S., Dykes, K., O'Connor, T., Ahmed, M., Gupta, et al
  LIPPINCOTT WILLIAMS & WILKINS.2023

- **Next-Generation Sequencing-Based MRD in Adults with ALL Undergoing Hematopoietic Cell Transplantation.** *Blood advances*
  Liang, E. C., Dekker, S. E., Sabile, J. M., Torelli, S., Zhang, A., Miller, K., Shiraz, P., Hayes-Lattin, B., Leonard, J. T., Muffly, L.
  2023

- **Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.** *Blood*
  Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., Frank, M. J., Johnston, L. J., Miklos, D. B., Muffly, L., Negrin, R. S., Rezvani, A. R., Shiraz, et al
  2023

- **Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.** *American journal of hematology*
  Aldoss, I., Shah, B. D., Park, J. H., Muffly, L., Logan, A. C., Brown, P., Stock, W., Jabbour, E. J.
  2023

- **Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy.** *The Neurohospitalist*
  Satyanarayan, S., Spiegel, J., Hovsepian, D., Markert, M., Thomas, R., Muffly, L., Miklos, D., Graber, K., Scott, B. J.
  2023; 13 (1): 53-60

- **Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.** *Haematologica*
  Saygin, C., Cannova, J., Stock, W., Muffly, L.
  2022; 107 (12): 2783-2793

- **CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study**
  Jeyakumar, N., Ramakrishna, S., Frank, M. J., Sahaf, B., Feldman, S. A., Miklos, D. B., Mackall, C. L., Davis, K. L., Muffly, L., Schultz, L. M.
  AMER SOC HEMATOLOGY.2022: 2374-2375

- **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**
  Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al
  AMER SOC HEMATOLOGY.2022: 7545-7547

- **The Development of CarhIh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes**
  Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, et al
  AMER SOC HEMATOLOGY.2022: 12775-12777

- **Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma**
  Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., Latchford, T., Arai, S., Johnston, L. J., Lowsky, R., Negrin, R. S., Rezvani, A. R., Shizuru, et al
  AMER SOC HEMATOLOGY.2022: 10371-10373

- **Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease**
  Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., Rezvani, A. R., Frank, M. J., Bharadwaj, S., Weng, W., Negrin, R. S., Miklos, D. B., Arai, et al
  AMER SOC HEMATOLOGY.2022: 4788-4789

- **Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era**

Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Bharadwaj, S., Frank, et al

AMER SOC HEMATOLOGY.2022: 4825-4827

- **Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018**

  Valcarcel, B., Schonfeld, S. J., Meyer, C. L., Brunson, A. M., Cooley, J. J. P., Abrahao, R., Wun, T., Auletta, J., Muffly, L., Keegan, T. H. M., Morton, L. M.

  AMER SOC HEMATOLOGY.2022: 7684-7685

- **Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data**

  Schonfeld, S. J., Valcarcel, B., Meyer, C. L., Brunson, A. M., Cooley, J. J. P., Abrahao, R., Wun, T., Auletta, J., Muffly, L., Keegan, T. H. M., Morton, L. M.

  AMER SOC HEMATOLOGY.2022: 7670-7671

- **Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California**

  Esteghamat, N. S., Brunson, A. M., Wun, T., Rosenberg, A. S., Cooley, J. J. P., Schonfeld, S. J., Meyer, C. L., Valcarcel, B., Abrahao, R., Auletta, J., Morton, L. M., Muffly, L., Keegan, et al

  AMER SOC HEMATOLOGY.2022: 10060-10062

- **Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study**

  Muffly, L., Young, C., Xie, B., Block, A., Touya, M., Pandya, B. J.

  AMER SOC HEMATOLOGY.2022: 8111-8112

- **Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation**

  Schultz, L. M., Ramakrishna, S., Baskar, R., Richards, R. M., Moon, J., Baggott, C., Fujimoto, M., Kunicki, M., Li, A., Jariwala, S., Erickson, C., Jacobs, A., Yamabe, et al

  AMER SOC HEMATOLOGY.2022: 10300-10302

- **Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity**

  Oliai, C., Hoeg, R. T., Pavlova, A., Gandhi, A., Muffly, L., Mehta, R. S., Srour, S. A., Waller, E. K., Lowsky, R., Patel, S. S., Dholaria, B., Bachier, C., Pantin, et al

  AMER SOC HEMATOLOGY.2022

- **Interim Update on the 'Watch' Registry, a Real-World Observational Study Using Clonoseq (R) to Monitor MRD in Lymphoid Malignancies**

  Patel, K., Svoboda, J., Shah, B. D., Cheson, B. D., Azzi, G., Patel, K., Cowan, A. J., Muffly, L., Simmons, H., Schliekelman, M., Leonard, J.

  AMER SOC HEMATOLOGY.2022: 5192-5194

- **Geographical Barriers to Accessing Specialty Cancer Care Among Adolescents and Young Adults with Acute Lymphoblastic Leukemia**

  Muffly, L., Garcia, A., Miller, K., Keegan, T. H. M., Parsons, H.

  AMER SOC HEMATOLOGY.2022: 2402-2403

- **Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation**

  Liang, E. C., Dekker, S. E., Sabile, J. M. G., Torelli, S., Zhang, A., Miller, K., Shiraz, P., Hayes-Lattin, B., Leonard, J., Muffly, L.

  AMER SOC HEMATOLOGY.2022: 1732-1733

- **Impact on caregivers and families of patients receiving chimeric antigen receptor T-cell therapy: a prospective longitudinal mixed methods study**

  Litovich, C., Piehowski, C., Akinola, I., Crawford, E., D'Souza, A., Frank, M., Flynn, K., Knight, J., Lahijani, S., Miklos, D., Muffly, L., Sadana, S., Shah, et al

  SPRINGER.2022: S145

- **Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy** *NEUROHOSPITALIST*

  Satyanarayan, S., Spiegel, J., Hovsepian, D., Markert, M., Thomas, R., Muffly, L., Miklos, D., Graber, K., Scott, B. J.

  2022

- **CT-095 Disparities and Incomplete Capture of Race/Ethnicity Data in Adults With Hematologic Malignancies Referred for Cellular Therapies.** *Clinical lymphoma, myeloma & leukemia*
  Molina, A., Muffly, L.
  2022; 22 Suppl 2: S433-S434

- **Disparities and Incomplete Capture of Race/Ethnicity Data in Adults With Hematologic Malignancies Referred for Cellular Therapies**
  Molina, A., Muffly, L.
  CIG MEDIA GROUP, LP.2022: S433-S434

- **Linking the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry to the California Cancer Registry and California Hospital Patient Discharge Data.** *Transplantation and cellular therapy*
  Keegan, T. H., Brunson, A., Cooley, J. J., Schonfeld, S. J., Meyer, C. L., Valcarcel, B., Abrahao, R., Wun, T., Auletta, J., Muffly, L., Morton, L. M.
  2022

- **Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy** *NATURE MEDICINE*
  Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., Desai, M. H., Reynolds, W. D., Lin, A., Vandris, P., Wu, F., Prabhu, S., Hamilton, et al
  2022

- **Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis.** *Leukemia & lymphoma*
  Namjoshi, N. S., Keegan, T. H., Li, Q. C., Chung, J. H., Rosenthal, J. L., Winestone, L. E., Muffly, L., Malogolowkin, M. H., Alvarez, E. M.
  2022: 1-9

- **SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond.** *Clinical lymphoma, myeloma & leukemia*
  Dekker, S. E., Leonard, J., Muffly, L.
  2022

- **Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.** *Blood advances*
  Muffly, L., Yin, J., Jacobson, S., Wall, A., Quiroz, E., Advani, A. S., Luger, S. M., Tallman, M. S., Litzow, M. R., Foster, M. C., Erba, H. P., Appelbaum, F. R., Larson, et al
  2022; 6 (14): 4085-4092

- **Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia** *BLOOD ADVANCES*
  Muffly, L., Yin, J., Jacobson, S., Wall, A., Quiroz, E., Advani, A. S., Luger, S. M., Tallman, M. S., Litzow, M. R., Foster, M. C., Erba, H. P., Appelbaum, F. R., Larson, et al
  2022; 6 (14): 4085-4092

- **Measurable residual disease in acute lymphoblastic leukemia: techniques and therapeutic utility.** *Clinical advances in hematology & oncology : H&O*
  Muffly, L.
  2022; 20 (7): 419-421

- **Measurable Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Therapeutic Utility** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
  Muffly, L.
  2022; 20 (7): 419-421

- **Reverse fate mapping of CD19-targeted CAR T cells in patients with large B-cell lymphoma**
  Good, Z., Hamilton, M. P., Spiegel, J. Y., Kurra, S., Desai, M., Prabhu, S., Yang, E., Ozawa, M. G., Hanson, P. J., Wu, F., Frank, M. J., Baird, J. H., Muffly, et al
  AMER ASSOC CANCER RESEARCH.2022

- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
  Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
  2022

- **Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*

Curran, E., Muffly, L., Luskin, M. R.
2022; 42: 1-11

- **Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.** *Current oncology reports*
  Grover, P., Muffly, L.
  2022

- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
  Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
  1800

- **Correction to: Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.** *Bone marrow transplantation*
  Liang, E. C., Chen, C., Lu, R., Mannis, G. N., Muffly, L.
  2022

- **Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.** *American journal of hematology*
  Kennedy, V. E., Hui, G., Azenkot, T., Gaut, D., Wieduwilt, M. J., Oliai, C., Jonas, B. A., Mittal, V., Logan, A. C., Muffly, L. S., Mannis, G. N.
  2022

- **Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Luznik, L., Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, et al
  2021: JCO2102293

- **Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study**
  Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., Muffly, L., Johnston, L. J., Arai, S., Lowsky, R., Meyer, E. H., Rezvani, A. R., Weng, et al
  AMER SOC HEMATOLOGY.2021

- **Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation**
  Liang, E. C., Chen, C., Lu, R., Mannis, G. N., Muffly, L.
  AMER SOC HEMATOLOGY.2021

- **Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a US Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with US Population-Level Data**
  Muffly, L., Yin, J., Jacobson, S., Advani, A., Luger, S. M., Tallman, M. S., Litzow, M. R., Foster, M. C., Appelbaum, F. R., Larson, R. A., Keegan, T., Stock, W.
  AMER SOC HEMATOLOGY.2021

- **First Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia: Associated Health Care Resource Use and Costs**
  Muffly, L., Young, C., Nimke, D., Sullivan, L., Feng, Q., Pandya, B. J.
  AMER SOC HEMATOLOGY.2021: 1936-+

- **Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study**
  Cusatis, R., Tan, I., Piehowski, C., Akinola, I., Crawford, E., Craig, J., Thiengmany, A., Frank, M. J., Miklos, D. B., Shah, N. N., D'Souza, A., Knight, J. M., Muffly, et al
  AMER SOC HEMATOLOGY.2021

- **Do PROs Tell the Whole Story? Differential Outcomes Based on PatientReported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy**
  Tan, I., Cusatis, R., Crawford, E., Thiengmany, A., Piehowski, C., Akinola, I., Craig, J., Lahijani, S., Frank, M. J., Shah, N. N., D'Souza, A., Miklos, D. B., Muffly, et al

AMER SOC HEMATOLOGY.2021

- **Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors**
  Arpita, G., Moroz, A., Muffly, L., Shiraz, P., Schachter, L., Fernhoff, N. B., McClellan, J., Negrin, R. S., Gotlib, J., Meyer, E. H.
  AMER SOC HEMATOLOGY.2021: 1819-+

- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
  Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al
  2021; 5 (21): 4465-4475

- **Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon?** *Blood reviews*
  El Fakih, R., Lazarus, H. M., Muffly, L., Altareb, M., Aljurf, M., Hashmi, S. K.
  2021: 100892

- **Chimeric Antigen Receptor-T Cell Therapy in Adults with B-Cell Acute Lymphoblastic Leukemia: A Systematic Review.** *Blood advances*
  Grover, P., Veilleux, O., Tian, L., Sun, R., Previtera, M., Curran, E., Muffly, L.
  2021

- **Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.** *Blood advances*
  Wieduwilt, M. J., Metheny, L., Zhang, M., Wang, H., Estrada-Merly, N., Marks, D. I., Al-Homsi, A. S., Muffly, L., Chao, N. J., Rizzieri, D., Gale, R. P., Gadalla, S. M., Cairo, et al
  2021

- **Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Systematic Review and Meta-Analysis**
  Grover, P., Veilleux, O., Tian, L., Sun, R., Previtera, M., Curran, E., Muffly, L.
  CIG MEDIA GROUP, LP.2021: S454

- **Measurable Residual Disease in Acute Lymphoblastic Leukemia: Optimization and Innovation in 2021 and Beyond**
  Muffly, L.
  CIG MEDIA GROUP, LP.2021: S85-S87

- **Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation**
  Liang, E. C., Chen, C., Lu, R., Mannis, G. N., Muffly, L.
  CIG MEDIA GROUP, LP.2021: S278-S279

- **Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era.** *Cancer*
  Kennedy, V. E., Keegan, T. H., Li, Q., Maguire, F. B., Muffly, L. S.
  2021

- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
  Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
  2021; 5 (16): 3147-3151

- **Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.** *Haematologica*
  Lazaryan, A., Dolan, M., Zhang, M., Wang, H., Kharfan-Dabaja, M. A., Marks, D. I., Bejanyan, N., Copelan, E., Majhail, N. S., Waller, E. K., Chao, N., Prestidge, T., Nishihori, et al
  2021; 106 (8): 2295-2296

- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
  Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
  2021

- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
  Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
  2021

- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**
  Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffly, et al
  SPRINGERNATURE.2021: 181

- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**
  Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al
  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Implementation of a clinic to facilitate the transition from pediatric to adult cancer survivorship care.**
  Smith, S. M., Jin, A., Simon, P., Clayton, A., Benedict, C., Liedtke, M., Muffly, L. S., Schapira, L.
  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.**
  Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., Liedtke, M.
  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults: a population-based study.** *International journal of epidemiology*
  Abrahao, R., Huynh, J. C., Benjamin, D. J., Li, Q. W., Winestone, L. E., Muffly, L., Keegan, T. H.
  2021; 50 (2): 663-674

- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
  Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
  2021

- **Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.** *Transplantation and cellular therapy*
  Bhatt, N. S., Brazauskas, R., Salit, R. B., Syrjala, K., Bo-Subait, S., Tecca, H., Badawy, S. M., Baker, K. S., Beitinjaneh, A., Bejanyan, N., Byrne, M., Dias, A., Farhadfar, et al
  2021

- **Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients.** *Transplantation and cellular therapy*
  Tan, I. T., Sundaram, V., Ramirez, Y., Burnash, S., Kate Tierney, D., Muffly, L. S.
  2021

- **Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.** *Blood advances*
  El Chaer, F., Borate, U., Dulery, R., Holtan, S. G., Law, A. D., Muffly, L., Nassereddine, S., Shallis, R. M., Stringaris, K., Taylor, J., Devine, S. M., Mohty, M., Hourigan, et al
  2021; 5 (6): 1757–59

- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
  Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
  2021

- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.** *Blood advances*
  Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al

2021; 5 (1): 143-155

- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
  Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
  2021; 5 (1): 143–55

- **Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.** *Leukemia & lymphoma*
  Ladha, A. n., Hui, G. n., Cheung, E. n., Berube, C. n., Coutre, S. E., Gotlib, J. n., Liedtke, M. n., Zhang, T. Y., Muffly, L. n., Mannis, G. N.
  2021: 1–6

- **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*
  Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al
  2021

- **Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.** *Bone marrow transplantation*
  Liang, E. C., Chen, C., Lu, R., Mannis, G. N., Muffly, L.
  2021

- **Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry.** *Transplantation and cellular therapy*
  Cusatis, R., Flynn, K. E., Vasu, S., Pidala, J., Muffly, L., Uberti, J., Tamari, R., Mattila, D., Mussetter, A., Bruzauskas, R., Chen, M., Leckrone, E., Myers, et al
  2021

- **Allogeneic hematopoietic cell transplantation (alloHCT) for patients over 65 years old is not associated with worse symptoms/function than younger patients - a Center for International Blood and Marrow Transplant Research (CIBMTR) study**
  Shaw, B., Brazauskas, R., Burns, L. J., Mattila, D., Musseter, A., Chen, M., Vasu, S., Pidala, J., Muffly, L., Uberti, J., Tamari, R., Tamari, R., Leckrone, et al
  SPRINGER.2020: S29

- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
  2020

- **How I Approach the Patient Who Has MRD or Relapse After Transplant** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
  Muffly, L.
  2020; 20: S32–S33

- **Late Effects in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia.** *JNCI cancer spectrum*
  Muffly, L., Maguire, F. B., Li, Q., Kennedy, V., Keegan, T. H.
  2020; 4 (4): pkaa025

- **Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020.** *Seminars in hematology*
  Muffly, L., Kebriaei, P.
  2020; 57 (3): 137–41

- **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**
  Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al
  LIPPINCOTT WILLIAMS & WILKINS.2020

- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
  Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al

LIPPINCOTT WILLIAMS & WILKINS.2020

- **Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.** *Current hematologic malignancy reports*
  Yurkiewicz, I., Craig, J., Muffly, L.
  2020
- **Access to specialized care and outcomes in adults with acute leukemias** *BLOOD ADVANCES*
  Muffly, L., Bhatt, V. R.
  2020; 4 (7): 1538
- **Access to specialized care and outcomes in adults with acute leukemias.** *Blood advances*
  Muffly, L., Bhatt, V. R.
  2020; 4 (7): 1538
- **Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.** *Blood advances*
  Lee, C. J., Kim, S., Tecca, H. R., Bo-Subait, S., Phelan, R., Brazauskas, R., Buchbinder, D., Hamilton, B. K., Battiwalla, M., Majhail, N. S., Lazarus, H. M., Shaw, P. J., Marks, et al
  2020; 4 (6): 983–92
- **The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.** *International journal of molecular sciences*
  Shiraz, P., Payne, K. J., Muffly, L.
  2020; 21 (6)
- **Assessment of Measurable Residual Disease (MRD) in Adult Patients With Acute Lymphocytic Leukemia: Best Use and a Case Report** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
  Muffly, L.
  2020; 18 (3)
- **Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool**
  Mishra, A., Preussler, J. M., Al-Mansour, Z., Bachanova, V., Bhatt, V., Bredeson, C., Chhabra, S., D'Souza, A., Dahi, P. B., DeFilipp, Z., Gowda, L., Hacker, E., Hashmi, et al
  ELSEVIER SCIENCE INC.2020: S45–S46
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
  Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
  ELSEVIER SCIENCE INC.2020: S106
- **Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients With Hematologic Malignancies: A Case-Based Monograph** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
  Wolf, J., Fonseca, R., Muffly, L.
  2020; 18 (3)
- **Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients**
  Muffly, L., Ramirez, Y., Burnash, S., Bisetti, E., Rezvani, A., Sundaram, V.
  ELSEVIER SCIENCE INC.2020: S199
- **Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool**
  Mishra, A., Preussler, J. M., Al-Mansour, Z., Bachanova, V., Bhatt, V., Bredeson, C., Chhabra, S., D'Souza, A., Dahi, P. B., DeFilipp, Z., Gowda, L., Hacker, E., Hashmi, et al
  ELSEVIER SCIENCE INC.2020: S45–S46
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
  Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
  ELSEVIER SCIENCE INC.2020: S106

- **Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients With Hematologic Malignancies: A Case-Based Monograph** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
  Wolf, J., Fonseca, R., Muffly, L.
  2020; 18 (3)

- **Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.** *Leukemia & lymphoma*
  Ladha, A. n., Mannis, G. n., Muffly, L. n.
  2020: 1–7

- **Calcineurin-inhibitor induced pain syndrome after stem cell transplant.** *Leukemia & lymphoma*
  Varma, A. n., Loya, J. n., Junaid Hussain, M. n., Don Yun, H. n., Gobbi, E. K., Reimer, A. n., Nathan, S. n., Ustun, C. n., Muffly, L. n.
  2020: 1–4

- **Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults.** *JCO oncology practice*
  Wang, A. Y., Muffly, L. S., Stock, W. n.
  2020: JOP1900197

- **How I Approach the Patient Who Has MRD or Relapse After Transplant.** *Clinical lymphoma, myeloma & leukemia*
  Muffly, L. n.
  2020; 20 Suppl 1: S32–S33

- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*
  Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al
  2020

- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*
  Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al
  2020; 4 (18): 4474–82

- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
  Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
  2020

- **Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia.** *JCO oncology practice*
  Alvarez, E. M., Malogolowkin, M. n., Hoch, J. S., Li, Q. n., Brunson, A. n., Pollock, B. H., Muffly, L. n., Wun, T. n., Keegan, T. H.
  2020: JOP1900572

- **Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?**
  Muffly, L., Curran, E.
  AMER SOC HEMATOLOGY.2019: 17–23

- **Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents**
  Sica, R., Spinner, M. A., Tamaresis, J. S., Advani, R. H., Johnston, L. J., Lowsky, R., Meyer, E. H., Miklos, D. B., Muffly, L. S., Rezvani, A. R., Shizuru, J. A., Weng, W., Negrin, et al
  AMER SOC HEMATOLOGY.2019

- **Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type**
  Muffly, L. S., Maguire, F., Li, Q., Kennedy, V., Keegan, T. H. M.
  AMER SOC HEMATOLOGY.2019

- **Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel**
  Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Frank, M. J., Baird, J., Muffly, L. S., Claire, G. K., Craig, J., Kong, K. A., Bendall, S., Miklos, D. B., Mackall, et al

AMER SOC HEMATOLOGY.2019

- **Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)**
  Schultz, L. M., Muffly, L. S., Spiegel, J. Y., Ramakrishna, S., Hossain, N., Baggott, C., Sahaf, B., Patel, S., Craig, J., Yoon, J., Kadapakkam, M., Majzner, R. G., Frank, et al
  AMER SOC HEMATOLOGY.2019

- **Central Nervous System Relapse in Adolescents and Young Adults with Acute Lymphoblastic Lymphoma Treated with Total Body Irradiation and Hematopoietic Stem Cell Transplantation**
  Kozak, M., Yoo, C., Muffly, L., Hiniker, S. M.
  ELSEVIER SCIENCE INC.2019: E472

- **Comparison of high doses of total body irradiation in myeloablative conditioning prior to hematopoietic cell transplantation.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Sabloff, M., Chhabra, S., Wang, T., Fretham, C., Kekre, N., Abraham, A., Adekola, K., Auletta, J. J., Barker, C., Beitinjaneh, A. M., Bredeson, C., Cahn, J., Diaz, et al
  2019

- **Healthcare Utilization is High in Adult Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Langston, J. A., Sundaram, V., Periyakoil, V. S., Muffly, L.
  2019; 25 (8): 1659–65

- **Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Lin, J. K., Muffly, L. S., Spinner, M. A., Barnes, J. I., Owens, D. K., Goldhaber-Fiebert, J. D.
  2019: JCO1802079

- **Hematopoietic Cell Transplantation in Young Adult Acute Lymphoblastic Leukemia: A United States Population-Level Analysis** *JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY*
  Muffly, L., Li, Q., Alvarez, E., Kahn, J., Winestone, L., Cress, R., Penn, D. C., Keegan, T. H. M.
  2019; 8 (3): 254–61

- **Acute leukemia in a patient with 15q overgrowth syndrome** *AMERICAN JOURNAL OF MEDICAL GENETICS PART A*
  Bodle, E. E., Gupta, R., Cherry, A. M., Muffly, L., Manning, M. A.
  2019; 179 (6): 1025–29

- **Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.**
  Lin, J., Muffly, L. S., Spinner, M., Barnes, J. I., Owens, D. K., Goldhaber-Fiebert, J. D.
  AMER SOC CLINICAL ONCOLOGY.2019

- **Delays in diagnosis in young patients with leukemia and lymphoma.**
  Winestone, L., McPheeters, J., Puccetti, D., Wilkes, J., Muffly, L. S., Kahn, J., Henk, H. J., Ginsberg, J. P., Keegan, T., Pollock, B. H., Alvarez, E.
  AMER SOC CLINICAL ONCOLOGY.2019

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
  Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
  2019; 4 (10)

- **EEG Findings in Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome**
  Satyanarayan, S., Markert, M., Hovsepian, D., Post, D., Muffly, L., Miklos, D., Thomas, R., Scott, B.
  LIPPINCOTT WILLIAMS & WILKINS.2019

- **Health Care Utilization is High in Adult Patients Relapsing After Allogeneic Hematopoietic Cell Transplantation.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Langston, J. A., Sundaram, V., Periyakoil, V. S., Muffly, L.
  2019

- **Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California** *JOURNAL OF ONCOLOGY PRACTICE*
  Alvarez, E. M., Malogolowkin, M., Li, Q., Brunson, A., Pollock, B. H., Muffly, L., Wun, T., Keegan, T. H. M.

2019; 15 (4): 200-+

- **Acute leukemia in a patient with 15q overgrowth syndrome.** *American journal of medical genetics. Part A*
  Bodle, E. E., Gupta, R., Cherry, A. M., Muffly, L., Manning, M. A.
  2019
- **Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California.** *Journal of oncology practice*
  Alvarez, E. M., Malogolowkin, M., Li, Q., Brunson, A., Pollock, B. H., Muffly, L., Wun, T., Keegan, T. H.
  2019: JOP1800264
- **Does Treatment Setting Matter? Evaluating Resource Utilization for Adolescents Treated in Pediatric vs Adult Cancer Institutions** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
  Parsons, H. M., Muffly, L., Alvarez, E. M., Keegan, T. H. M.
  2019; 111 (3): 224–25
- **Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients**
  Gandhi, A., Rezvani, A., Lowsky, R., Johnston, L., Shizuru, J. A., Miklos, D. B., Arai, S., Muffly, L., Meyer, E. H., Negrin, R. S., Weng, W.
  ELSEVIER SCIENCE INC.2019
- **Does Treatment Setting Matter? Evaluating Resource Utilization for Adolescents Treated in Pediatric vs Adult Cancer Institutions.** *Journal of the National Cancer Institute*
  Parsons, H. M., Muffly, L., Alvarez, E. M., Keegan, T. H.
  2019; 111 (3): 224–25
- **Health Care Utilization and Intensity at End of Life is High Amongst Adults Who Relapse Following Allogeneic Hematopoietic Cell Transplantation**
  Langston, J., Sundaram, V., Periyakoil, V., Muffly, L.
  ELSEVIER SCIENCE INC.2019: 506
- **Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions** *EXPERT REVIEW OF HEMATOLOGY*
  Kennedy, V. E., Muffly, L. S.
  2019; 12 (2): 99-106
- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy** *LEUKEMIA & LYMPHOMA*
  Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., Miklos, D. B.
  2019; 60 (2): 503-506
- **Hematopoietic Cell Transplantation in Young Adult Acute Lymphoblastic Leukemia: A United States Population-Level Analysis.** *Journal of adolescent and young adult oncology*
  Muffly, L., Li, Q., Alvarez, E., Kahn, J., Winestone, L., Cress, R., Penn, D. C., Keegan, T. H.
  2019
- **Assessment of Older Adult Candidates for Allogeneic Hematopoietic Cell Transplantation: Updates and Remaining Questions.** *Expert review of hematology*
  Kennedy, V. E., Muffly, L. S.
  2019
- **Transplant for Acute Myeloid Leukemia in Patients Seventy Years and Older: Optimism and Opportunity.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Muffly, L. n.
  2019
- **Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?** *Hematology. American Society of Hematology. Education Program*
  Muffly, L. n., Curran, E. n.
  2019; 2019 (1): 17–23

- **Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.** *Haematologica*
  Lazaryan, A. n., Dolan, M. n., Zhang, M. J., Wang, H. L., Kharfan-Dabaja, M. A., Marks, D. I., Bejanyan, N. n., Copelan, E. n., Maijhail, N. n., Waller, E. K., Chao, N. n., Prestidge, T. n., Nishihori, et al
  2019

- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
  2019; 3 (16): 2454–64

- **Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience.** *Journal of adolescent and young adult oncology*
  Kozak, M. M., Yoo, C. H., Gutkin, P. M., von Eyben, R. n., Agarwal, R. n., Donaldson, S. S., Muffly, L. n., Hiniker, S. M.
  2019

- **Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma** *Journal of Clinical Oncology*
  Lin, J. K., Muffly, L. S., Spinner, M. A., Barnes, J. I., Owens, D. K., Goldhaber-Fiebert, J. D.
  2019

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.** *JCI insight*
  Meyer, E. H., Laport, G. n., Xie, B. J., MacDonald, K. n., Heydari, K. n., Sahaf, B. n., Tang, S. W., Baker, J. n., Armstrong, R. n., Tate, K. n., Tadisco, C. n., Arai, S. n., Johnston, et al
  2019; 4 (10)

- **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al
  AMER SOC HEMATOLOGY.2018

- **Health Care Utilization Is High Amongst Adults Who Relapse Following Allogeneic Hematopoietic Cell Transplantation**
  Langston, J., Sundaram, V., Periyakoil, V., Muffly, L. S.
  AMER SOC HEMATOLOGY.2018

- **Disparities in Cancer-Related Mortality and Long-Term Survival in Adolescent and Young Adults with Hodgkin Lymphoma: A Population-Level Analysis across the United States**
  Kahn, J. M., Keegan, T. H. M., Alvarez, E., Muffly, L. S., Parsons, H., Winestone, L. E., Bleyer, A.
  AMER SOC HEMATOLOGY.2018

- **Hematopoietic Cell Transplantation in First Remission Amongst Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Level Analysis across the United States**
  Muffly, L. S., Li, Q., Alvarez, E., Kahn, J. M., Winestone, L. E., Cress, R., Penn, D., Keegan, T. H. M.
  AMER SOC HEMATOLOGY.2018

- **Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies**
  Hossain, N., Sahaf, B., Abramian, M., Spiegel, J. Y., Kong, K., Kim, S., Mavroukakis, S., Oak, J., Natkunam, Y., Meyer, E. H., Frank, M. J., Feldman, S. A., Long, et al
  AMER SOC HEMATOLOGY.2018

- **Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**
  Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al
  AMER SOC HEMATOLOGY.2018

- **Health Care Utilization Is High Amongst Adults Who Relapse Following Allogeneic Hematopoietic Cell Transplantation**
  Langston, J., Sundaram, V., Periyakoil, V., Muffly, L. S.
  AMER SOC HEMATOLOGY.2018

- **Disparities in Cancer-Related Mortality and Long-Term Survival in Adolescent and Young Adults with Hodgkin Lymphoma: A Population-Level Analysis across the United States**
  Kahn, J. M., Keegan, T. H. M., Alvarez, E., Muffly, L. S., Parsons, H., Winestone, L. E., Bleyer, A.
  AMER SOC HEMATOLOGY.2018

- **Hematopoietic Cell Transplantation in First Remission Amongst Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Level Analysis across the United States**
  Muffly, L. S., Li, Q., Alvarez, E., Kahn, J. M., Winestone, L. E., Cress, R., Penn, D., Keegan, T. H. M.
  AMER SOC HEMATOLOGY.2018

- **Another reason to encourage psychosocial risk assessment in hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
  Muffly, L., Artz, A.
  2018; 53 (11): 1416-1417

- **End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis** *JOURNAL OF CLINICAL ONCOLOGY*
  Johnston, E. E., Muffly, L., Alvarez, E., Saynina, O., Sanders, L. M., Bhatia, S., Chamberlain, L. J.
  2018; 36 (30)

- **Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California.** *Leukemia & lymphoma*
  Alvarez, E., Muffly, L., Li, Q., Brunson, A., Wun, T., Chamberlain, L., Keegan, T.
  2018; 59 (10): 2482–84

- **Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens** *AMERICAN JOURNAL OF HEMATOLOGY*
  Siegel, S. E., Advani, A., Seibel, N., Muffly, L., Stock, W., Luger, S., Shah, B., DeAngelo, D. J., Freyer, D. R., Douer, D., Johnson, R. H., Hayes-Lattin, B., Lewis, et al
  2018; 93 (10): 1254–66

- **A Three-Step Letter Advance Directive Procedure to Facilitate Patient-Proxy Alignment in Advance Care Planning** *JOURNAL OF PALLIATIVE MEDICINE*
  Alagappan, M., Richardson, M. T., Schoen, M. K., Muffly, L., Tierney, K., Jenkins, P., Neri, E., Kraemer, H. C., Periyakoil, V. S.
  2018

- **End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Johnston, E. E., Muffly, L., Alvarez, E., Saynina, O., Sanders, L. M., Bhatia, S., Chamberlain, L. J.
  2018: JCO2018780957

- **Detection of Measurable Residual Disease by Next-Generation Sequencing in Paired Blood and Bone Marrow Samples from Patients with Lymphoid Malignancies**
  Miklos, D., Muffly, L., Lee, L., Crossley, B.
  CIG MEDIA GROUP, LP.2018: S295–S296

- **Minimal Residual Disease Monitoring of Acute Lymphoblastic Leukemia by High-Throughput Sequencing of the Peripheral Blood: Case Examples and Literature Review**
  Muffly, L.
  CIG MEDIA GROUP, LP.2018: S53–S55

- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.** *Leukemia & lymphoma*
  Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., Miklos, D. B.
  2018: 1–4

- **Improved survival among children and adolescent and young adults with acute lymphoblastic leukemia (ALL) treated at specialized cancer centers in California.**
  Alvarez, E., Malogolowkin, M. H., Li, Q., Muffly, L. S., Wun, T., Keegan, T.
  AMER SOC CLINICAL ONCOLOGY.2018

- **Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Review** *JAMA ONCOLOGY*

Siegel, S. E., Stock, W., Johnson, R. H., Advani, A., Muffly, L., Douer, D., Reed, D., Lewis, M., Freyer, D. R., Shah, B., Luger, S., Hayes-Lattin, B., Jaboin, et al
2018; 4 (5): 725–34

- **Advance Directive Utilization Is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Cappell, K., Sundaram, V., Park, A., Shiraz, P., Gupta, R., Jenkins, P., Periyakoil, V. S. J., Muffly, L.
  2018; 24 (5): 1035–40

- **Decreased Early Mortality Associated With the Treatment of Acute Myeloid Leukemia at National Cancer Institute-Designated Cancer Centers in California** *CANCER*
  Ho, G., Wun, T., Muffly, L., Li, Q., Brunson, A., Rosenberg, A. S., Jonas, B. A., Keegan, T. H. M.
  2018; 124 (9): 1938–45

- **Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study** *BLOOD ADVANCES*
  Muffly, L., Alvarez, E., Lichtensztajn, D., Abrahao, R., Gomez, S., Keegan, T.
  2018; 2 (8): 895–903

- **Another reason to encourage psychosocial risk assessment in hematopoietic cell transplantation.** *Bone marrow transplantation*
  Muffly, L., Artz, A.
  2018

- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
  Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
  2018; 2 (6): 681–90

- **Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells**
  Meyer, E., Laport, G. G., Tantsura, I., Tang, S., Sahaf, B., Rangarajan, K., Armstrong, R., Tate, K., Tudisco, C., Sheehan, K., Arai, S., Johnston, L., Muffly, et al
  ELSEVIER SCIENCE INC.2018: S145

- **Management of Acute Lymphoblastic Leukemia in Young Adults** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
  Muffly, L., Reizine, N., Stock, W.
  2018; 16 (2): 138–46

- **Advance Directive Utilization is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
  Cappell, K. n., Sundaram, V. n., Park, A. n., Shiraz, P. n., Gupta, R. n., Jenkins, P. n., Periyakoil, V. S., Muffly, L. n.
  2018

- **Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California** *LEUKEMIA & LYMPHOMA*
  Alvarez, E., Muffly, L., Li, Q., Brunson, A., Wun, T., Chamberlain, L., Keegan, T.
  2018; 59 (10): 2482-2484

- **Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia** *DRUG DESIGN DEVELOPMENT AND THERAPY*
  Yurkiewicz, I. R., Muffly, L., Liedtke, M.
  2018; 12: 2293–2300

- **Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.** *Blood advances*
  Spinner, M. A., Advani, R. H., Hoppe, R. T., Lowsky, R. n., Muffly, L. S.
  2018; 2 (13): 1547–50

- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
  2017; 23 (10): 1744–48

- **Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States** *BLOOD*
  Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M., Ballen, K. K., Bajel, A., Baron, F., Battiwalla, M., Beitinjaneh, A., Cahn, et al
  2017; 130 (9): 1156–64

- **Coordination of Care in Survivorship After Treatment of Hematological Malignancies-The Journey is Not Over Yet.** *Current hematologic malignancy reports*
  Lee, C. J., Muffly, L. S.
  2017

- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR-T therapy.**
  Dahiya, S., Le, R., Hossain, N., Abramian, M., Muffly, L. S., Miklos, D.
  AMER SOC CLINICAL ONCOLOGY.2017

- **Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.** *Leukemia & lymphoma*
  Lee, C. J., Shiraz, P., Muffly, L.
  2017; 58 (3): 516-527

- **Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era**
  Sabloff, M., Wang, T., Zhu, X., Artz, A. S., Adekola, K., Abraham, A., Auletta, J. J., Battiwalla, M., Beitinjaneh, A., Bredeson, C. N., Martino Bufarull, R., Cahn, J., Cerny, et al
  ELSEVIER SCIENCE INC.2017: S81-S82

- **Integrating cancer survivorship care into allogeneic BMT recovery.**
  Bugos, K., Stenger, S., Smith, A., Johnston, L., Gross, M., Knight, G., Lambert, S., Muffly, L. S.
  AMER SOC CLINICAL ONCOLOGY.2017

- **My Patient, the Superhero.** *Journal of clinical oncology*
  Muffly, L.
  2017: JCO2016696005-?

- **Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.** *Leuk Lymphoma*
  CJ, L., P, S., L, M.
  2017; 58 (3): 516-527

- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
  Spinner, M. A., Fernández-Viña, M. n., Creary, L. E., Quinn, O. n., Elder, L. n., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
  2017; 1 (17): 1347–57

- **Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors**
  Spinner, M. A., Vina, M., Elder, L., Arai, S., Johnston, L., Meyer, E., Miklos, D., Muffly, L., Negrin, R. S., Shizuru, J., Weng, W., Laport, G. G., Strober, et al
  AMER SOC HEMATOLOGY.2016

- **Rate of Rise of EBV Viral Load By Quantitative PCR after Allogeneic Transplantation Correlates with PTLD Facilitates Timely Institution of Rituximab**
  Muffly, L. S., Shiraz, P., Nguyen, I. T., Brown, J. M.
  AMER SOC HEMATOLOGY.2016

- **Adolescent and Young Adult Oncology Patients with Acute Lymphoblastic Leukemia: Shifting Location of Care over Time**
  Alvarez, E., Muffly, L. S., Li, Q., Brunson, A. M., Wun, T., Chamberlain, L., Keegan, T.
  AMER SOC HEMATOLOGY.2016

- **Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation**

Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
AMER SOC HEMATOLOGY.2016

- **Symptom burdens and coping strategies in adolescent and young adult (AYA) cancer survivors with hematologic malignancies.**
  Hlubocky, F. J., Muffly, L. S., Gomez, J. X., Breitenbach, K., McNeer, J., Stock, W., Daugherty, C.
  AMER SOC CLINICAL ONCOLOGY.2016

- **Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.** *Cancer*
  Muffly, L., Lichtensztajn, D., Shiraz, P., Abrahão, R., McNeer, J., Stock, W., Keegan, T., Gomez, S. L.
  2016

- **Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.**
  Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L. S., Negrin, R., Rezvani, A. R., Shizuru, J., Weng, W., Johnston, L. J.
  AMER SOC CLINICAL ONCOLOGY.2016

- **Death anxiety, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship.**
  Hlubocky, F. J., Muffly, L. S., Gomez, J. X., Breitenbach, K., Cella, D., McNeer, J., Stock, W., Daugherty, C.
  AMER SOC CLINICAL ONCOLOGY.2016

- **Financial toxicity in children, adolescent, and young adult cancer patients and their families: A large national registry analysis from the family reach foundation**
  Muffly, L. S., Tardif, C., de Souza, J.
  AMER SOC CLINICAL ONCOLOGY.2016

- **Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.**
  Neppalli, A., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W., Negrin, R., Meyer, E., Laport, G., Lowsky, R., Arai, S., Miklos, D., Rezvani, A. R.
  AMER SOC CLINICAL ONCOLOGY.2016

- **Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship.** *Cancer*
  Muffly, L. S., Hlubocky, F. J., Khan, N., Wroblewski, K., Breitenbach, K., Gomez, J., McNeer, J. L., Stock, W., Daugherty, C. K.
  2016; 122 (6): 954-961

- **Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin**
  Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W., Arai, S., Johnston, L., Laport, G. G., Shizuru, J. A., Negrin, R., Strober, S., Lowsky, et al
  ELSEVIER SCIENCE INC.2016: S204–S205

- **Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes**
  Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M. D., Artz, A. S., Bajel, A., Ballen, K. K., Battiwalla, M., Beitinjaneh, A., Cahn, et al
  ELSEVIER SCIENCE INC.2016: S68–S69

- **Substance use, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship.**
  Hlubocky, F. J., Muffly, L. S., Gomez, J., Breitenbach, K., Lappe, M., Stock, W., Daugherty, C.
  AMER SOC CLINICAL ONCOLOGY.2016

- **Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms**
  Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., Galvez, L., Armstrong, R., Sheehan, K., Lowsky, R., Arai, S., Johnston, L., Miklos, et al
  AMER SOC HEMATOLOGY.2015

- **The overlooked COST of multiple myeloma.** *The Lancet. Haematology*
  de Souza, J. A., Muffly, L.

2015; 2 (10): e394-5

- **Secondary solid cancer screening following hematopoietic cell transplantation.** *Bone marrow transplantation*
  INAMOTO, Y., Shah, N. N., Savani, B. N., Shaw, B. E., Abraham, A. A., Ahmed, I. A., Akpek, G., Atsuta, Y., Baker, K. S., Basak, G. W., Bitan, M., DeFilipp, Z., GREGORY, et al
  2015; 50 (8): 1013-1023

- **Patient Selection for Allogeneic Hematopoietic Cell Transplantation (HCT): the Evolution of HCT Risk Assessment.** *Current hematologic malignancy reports*
  Muffly, L.
  2015; 10 (1): 28-34

- **Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy** *ANNALS OF ONCOLOGY*
  Abramson, J. S., Feldman, T., Kroll-Desrosiers, A. R., Muffly, L. S., Winer, E., Flowers, C. R., Lansigan, F., Nabhan, C., Nastoupil, L. J., Nath, R., Goy, A., Castillo, J. J., Jagadeesh, et al
  2014; 25 (11): 2211-2217

- **Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients** *HAEMATOLOGICA*
  Muffly, L. S., Kocherginsky, M., Stock, W., Chu, Q., Bishop, M. R., Godley, L. A., Kline, J., Liu, H., Odenike, O. M., Larson, R. A., Van Besien, K., Artz, A. S.
  2014; 99 (8): 1373-1379

- **Hematopoietic cell transplantation in T-cell non-Hodgkin's lymphomas** *CANCER CONSULT: EXPERTISE FOR CLINICAL PRACTICE*
  Muffly, L. S., Smith, S. M.
  edited by Abutalib, S. A., Markman, M.
  2014: 339-344

- **Prognosis in diffuse large B-cell lymphoma The Picture Continues to Come Into Focus** *CANCER*
  Muffly, L. S., Smith, S. M.
  2013; 119 (6): 1129-1131

- **Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Muffly, L. S., Boulukos, M., Swanson, K., Kocherginsky, M., del Cerro, P., Schroeder, L., Pape, L., Extermann, M., Van Besien, K., Artz, A. S.
  2013; 19 (3): 429-434

- **Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience** *BREAST CANCER RESEARCH*
  Meaney, P. M., Kaufman, P. A., Muffly, L. S., Click, M., Poplack, S. P., Wells, W. A., Schwartz, G. N., di Florio-Alexander, R. M., Tosteson, T. D., Li, Z., Geimer, S. D., Fanning, M. W., Zhou, et al
  2013; 15 (2)

- **Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
  Maeda, L. S., Geiger, J. L., Savage, K. J., Rose, J., Pinter-Brown, L. C., Lunning, M. A., Abramson, J. S., Bartlett, N., Vose, J., Drape, J., Muffly, L. S., McMillan, A., Evens, et al
  AMER SOC CLINICAL ONCOLOGY.2012

- **Evaluation of Breast Tumor Response to Neoadjuvant Chemotherapy with Tomographic Diffuse Optical Spectroscopy: Case Studies of Tumor Region-of-Interest Changes** *RADIOLOGY*
  Jiang, S., Pogue, B. W., Carpenter, C. M., Poplack, S. P., Wells, W. A., Kogel, C. A., Forero, J. A., Muffly, L. S., Schwartz, G. N., Paulsen, K. D., Kaufman, P. A.
  2009; 252 (2): 551-560